In brief

Repeatedly exposing young children to antibiotics can cause an imbalance of gut microbiota that leads to obesity.

© Shutterstock

Clues to childhood obesity lie in our gut

30 Nov 2020

Early exposure to antibiotics can disrupt an infant’s gut microbiota and predispose them to childhood obesity, finds an observational study.

September may be the childhood obesity awareness month in the United States, but there is a growing epidemic around the world. According to the World Health Organization, childhood obesity is associated with an increased risk for serious health complications later in life, including diabetes and heart disease.

One factor influencing the initiation of obesity is an imbalance in the gut microbiota, the community of bacteria located in the intestines. A common cause of disruption in the normal colonization and development of infant gut microbiota is repeated antibiotic exposure—how this leads to weight gain in children is the missing piece in the puzzle.

“To our knowledge, no human study to date has evaluated the potential implication of the gut microbiota on the association between early antibiotic exposure and childhood obesity,” said Ling-Wei Chen, a Research Scientist at A*STAR’s Singapore Institute for Clinical Sciences (SICS). To address this gap, Chen and SICS colleague Jia Xu conducted a prospective study studying infant antibiotic exposure and childhood obesity risk, and the contribution of gut microbiota to this association. The study was led by senior authors Neerja Karnani and Yung Seng Lee, both principal investigators at SICS.

More than a thousand women were recruited into the Growing Up in Singapore Towards healthy Outcomes (GUSTO) study, a collaboration between SICS, the National University of Singapore, KK Women’s and Children’s Hospital and the National University Hospital. This multi-ethnic, mother-offspring paired cohort resulted in 1,172 singleton births, which Chen and colleagues tracked over a five-year period.

From questionnaires answered by caregivers, combined with serial childhood weight and height measurements by trained staff, the research team found that 38 percent of infants in the study were exposed to antibiotics in their first year of life. This group had a higher risk of becoming obese until five years of age, particularly if they had been exposed to three or more courses of antibiotics.

At 24 months of age, the children’s stool samples were collected and sequenced to obtain their gut microbiota profile. Antibiotic use was associated with alterations to their gut microbiome, and these changes corresponded to a higher risk for adiposity within this group.

Interestingly, the researchers observed a stronger risk for obesity in boys exposed to antibiotics as compared to girls, but they still do not understand the mechanism behind this. The gender differences were only seen in infant fat storage and development, and not in the gut microbiota, Karnani noted.

Their results suggest the need for caution when administering antibiotics in children, and may assist doctors and caregivers in providing early intervention against obesity risk. “While in some instances antibiotics are necessary, our research calls for the careful consideration of the benefits versus risks in administering antibiotics, and the frequency of their use in children,” said Lee, who is also the Head of Pediatrics at the National University of Singapore’s Yong Loo Lin School of Medicine, and Head of the Khoo Teck Puat-National University Children’s Medical Institute.

The A*STAR-affiliated researchers contributing to this research are from the Singapore Institute for Clinical Sciences (SICS).

Want to stay up to date with breakthroughs from A*STAR? Follow us on Twitter and LinkedIn!


Chen, L., Xu, J., Soh, S.E., Aris, I.M., Tint, M.T., et al. Implication of gut microbiota in the association between infant antibiotic exposure and childhood obesity and adiposity accumulation. International Journal of Obesity 44, 1508–1520 (2020) | article

About the Researchers

Ling-Wei Chen is a research scientist at A*STAR’s Singapore Institute for Clinical Sciences (SICS) specializing in perinatal and pediatric epidemiology and nutrition. He was a recipient of the prestigious President’s Graduate Fellowship and graduated with a PhD degree in nutritional epidemiology from the National University of Singapore in 2014.
View articles

Neerja Karnani

Senior Principal Investigator

Singapore Institute for Clinical Sciences
Neerja Karnani is a Senior Principal Investigator and the Systems Biology Lead at A*STAR’s Singapore Institute for Clinical Sciences (SICS) and an Adjunct Associate Professor at the National University of Singapore’s Yong Loo Lin School of Medicine. She received her PhD degree in 2002 from Jawaharlal Nehru University, India, where her research was recognized with the C. R. Krishna Murti Memorial Young Scientist Award.

This article was made for A*STAR Research by Wildtype Media Group